Home › Pain After Surgery › NCT07548385
Suzetrigine for Treatment and Reduction of Intense Discomfort After knEe Replacement PAIN
Who can join
Ages 18 to 85 · All sexes
Full eligibility criteria
Inclusion Criteria: To be eligible to participate in this study, an individual must meet all of the following criteria: * Adults 18-85 years old * Scheduled to undergo total knee replacement surgery * All genders Exclusion Criteria: Any individual who meets any of the following criteria will be excluded from participation in this study: * American Society of Anesthesiology Physical Classification (ASA) Class V * Urgent or emergent surgery * Contraindications to administration of Suzetrigine: * Patients who take moderate-to-severe CYP3A inhibitors (such as Ritonavir, Voriconazole, and Clarithromycin) * Patients who take moderate-to-severe CYP3A inducers (such as Phenytoin, Carbamazapine, and Rifabutin) * Patients with moderate to severe hepatic impairment * History of substance use disorder or chronic opioid use or alcohol abuse * Reoperation * Patient refusal or inability to consent * Pregnancy
About the study
This is a prospective, randomized study. The purpose of this study is to evaluate if the addition of Suzetrigine, a new pain medication, to well established peri-operative pain regimen used for total knee replacement surgery will effect pain control.
1. Does Suzetrigine given pre-operatively decrease the total opioid consumed after total knee replacement surgery? 2. Dose Suzetrigine given pre-operatively decrease the visual analog pain scale pain scores after total knee replacement surgery? Study participants will be randomly assigned to receive either Suzetrigine medication or placebo medication.
What is being tested
- Suzetrigine (drug)
- Placebo (drug)
Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 235 · Started: 2026-04
Contact the study team
- Michael Lazar, MD · Phone: 212-523-2500
- Himani Bhatt, DO · Phone: 212-523-2500
Official record on ClinicalTrials.gov — NCT07548385
Locations in the U.S.
| New York | Mount Sinai West, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.